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Long non-coding RNAs (lncRNA) are emerging as new genetic/epigenetic regulators that
can impact almost all physiological functions. Here, we focus on the long non-coding
steroid receptor RNA activator (SRA), including new insights into its effects on gene
expression, the cell cycle, and differentiation; how these relate to physiology and disease;
and the mechanisms underlying these effects. We discuss how SRA acts as an RNA
coactivator in nuclear receptor signaling; its effects on steroidogenesis, adipogenesis,
and myocyte differentiation; the impact on breast and prostate cancer tumorigenesis;
and, finally, its ability to modulate hepatic steatosis through several signaling pathways.
Genome-wide analysis reveals that SRA regulates hundreds of target genes in adipocytes
and breast cancer cells and binds to thousands of genomic sites in human pluripotent
stem cells. Recent studies indicate that SRA acts as a molecular scaffold and forms
networks with numerous coregulators and chromatin-modifying regulators in both
activating and repressive complexes. We discuss how modifications to SRA’s unique
stem-loop secondary structure are important for SRA function, and highlight the various
SRA isoforms and mutations that have clinical implications. Finally, we discuss the future
directions for better understanding the molecular mechanisms of SRA action and how
this might lead to new diagnostic and therapeutic approaches.
Keywords: long non-coding RNA (lncRNA), steroid receptor RNA activator (SRA), physiological functions,
regulation of gene expression, differentiation
INTRODUCTION
Recent analysis of numerous high-throughput mammalian genomic platforms suggests that
protein-coding genes constitute only 2% of the genome, while many non-coding regulatory
elements are transcribed into non-coding RNA (ncRNA) (1–6). Increasing numbers of recent
studies have further revealed the importance of ncRNAs in the regulation of almost all biological
processes, including development, differentiation, metabolism, and disease pathogenesis (7–10).
Non-coding RNAs include a diverse group of transcripts, such as ribosomal RNA, transfer RNA,
small RNA, small nuclear RNA, small nucleolar RNA, regulatory ncRNAs, and other ncRNAs that
are yet to be fully characterized (11, 12). Regulatory ncRNAs can be defined according to their
size as small ncRNAs (<200 nt), such as micro RNA (miRNAs), endogenous small interfering
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RNAs (siRNA), and piwi-interacting RNA (piRNA); and long
ncRNA (lncRNAs), which are >200 nt in length. Small ncRNAs
have functions that include repressing target RNAs, and these
have been extensively studied. In contrast, lncRNAs have been
recently recognized to regulate gene expression through a range
of mechanisms, such as transcriptional regulation, modulation of
chromatin modification, and even organizing factors that impact
nuclear shape and structure (7, 13). So far, the number of new
and putative functional lncRNAs has greatly expanded, with over
16,000 and 8,000 lncRNAs annotated in the human and mouse
genomes, respectively (14). Based on their locations to nearby
protein-coding genes, lncRNAs can be classified into different
categories, including sense, antisense, divergent, and intergenic
lncRNAs (15).Most lncRNAs are transcribed by RNApolymerase
II and they are 5′ capped, polyadenylated, and spliced (16, 17).
Moreover, the expression of these lncRNAs is remarkably tissue-
specific and is highly regulated during development and in
response to physiological signals (18–22).
One notable lncRNA is the steroid receptor RNA activator
(SRA), which is encoded by the SRA1 gene. SRA was initially
identified in 1999 by a yeast two-hybrid assay in a human B-
lymphocyte library, in which the activation function 1 domain
(AF-1) of progesterone receptor (PR) was used as bait (23)
(Figure 1). SRA is intergenic and has a core sequence that in
humans is 687 bp in length. In addition, SRA was the first
lncRNA shown to act as a coactivator of steroid receptors (SRs),
including the androgen receptor (AR), estrogen receptor (ER),
glucocorticoid receptor (GR), and PR (23). Subsequent studies
revealed that SRA also functions as an RNA coactivator for
other type I and type II nuclear receptors (NRs), as well as the
transcription factorMyoD. Through thesemolecular interactions
and other pathways, SRA can impact numerous physiological and
pathological processes. For example, SRA has been reported to
regulate mammary gland development, myocyte, and adipocyte
differentiation, steroidogenesis, tumorigenesis, hepatic steatosis,
and stem cell function; indeed, aberrant SRA expression
and recent mutant variants have been identified in several
clinical samples (24–28). Thus, SRA is implicated in various
physiological contexts and may also be relevant to pathogenesis
of diverse diseases.
The Bifunctional Nature of SRA1: lncRNA
(SRA) vs. SRA Protein (SRAP)
An important consideration relates to the bifunctional nature of
the SRA1 locus. The SRA1 gene is unique in that it encodes not
only RNA transcripts (lncSRAs) of different lengths (23, 29) but
also produces, by alternative splicing, an mRNA that encodes
a 236/237 amino acid protein (30, 31) (Figure 1). To avoid
confusion, herein we refer to the gene as SRA1, the lncRNA as
SRA, and the protein as SRAP.
Both SRA and SRAP have biological functions (32) although,
compared to SRA, the physiological function of SRAP has
been less studied. Nevertheless, in vitro data reveals that SRAP
interacts with some transcription factors and may co-activate or
repress their activity depending on the cellular context (33–35).
For example, recent ChIP-on-chip arrays identified a long list
of SRAP-binding partners (including the steroid receptors ERα
and GR) and regions of SRAP-binding sites genome-wide (35).
These studies indicate that SRAP recruits to target promoters
and acts as transcriptional repressor. Recently described crystal
structures have further revealed that both mouse SRAP (residues
87–216) and human SRAP (residues 105–215) include a five-
helix X bundle structure (36, 37) and are structurally similar
to the carboxy-terminal domain of the yeast protein PRP18,
a splicing factor involved in interaction with RNA and pre-
mRNA splicing (38–40). Thus, another possibility is that SRAP
modulates splicing. In addition, phosphorylation of SRAP may
be involved in cell cycle regulation (41). Thus, SRAP is emerging
as a further means through which SRA1 can exert diverse
downstream effects.
A key implication of this bifunctionality is that one must be
cautious when interpreting the results of knockdown or knockout
of the endogenous SRA1 gene. For example, siRNA- or shRNA-
mediated knockdown may simultaneously deplete both SRA
and SRAP. Indeed, in our recently generated Sra1−/− mice we
found that, in the tissues examined, both SRA and SRAP are
lost (42). Consequently, in such systems one cannot conclude if
the functional change is due to the loss of either SRA or SRAP
only, or to the loss of both factors. In contrast, overexpression
systems have been able to mostly overcome this issue: use of the
pSCT-SRA plasmid allows for expression of SRA but not SRAP,
because this plasmid contains only the SRA core sequence (23).
Conversely, use of an SRAP plasmid allows expression of SRAP
but not SRA, because this plasmid contains silent mutations in
the major SRA stem loops and thereby causes defective SRA
activity (33, 43, 44). Even so, one cannot rule out the possible
roles of other stem loops and sub-structural domains of SRA, as
identified in the full crystal structure of SRA (45).
While these issues are essential to consider, studies to
date have focused more on SRA than on SRAP. Therefore,
in this review we will prioritize discussion of the lncRNA
SRA, including its molecular structure, impact on physiological
processes, mechanisms of action, and relevance to disease.
However, the functions and implications of SRAP will also be
discussed in cases where there is sufficient data to provide further
insights.
SRA STRUCTURE, EVOLUTION, AND
ISOFORMS
SRA Structure
Understanding the nature of SRA structure, and how this is
affected by sequence variation, is the molecular basis on which
to dissect its diverse functions. Lanz and colleagues generated
the secondary structure of SRA using phylogenetics, free energy
calculations, and a computational MFOLD program (43, 46). By
site-directed mutagenesis and functional assays they determined
that the distinct RNA motifs of SRA are important for its
coactivation activity (43). These motifs include 11 topological
substructures (STR 1–11) that are mainly located in the stem-
loop regions of the core sequence of human and mouse SRA.
Among these STRs, five motifs (STRs 1, 7, 9, 10, and 11)
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FIGURE 1 | Timeline of discovery of steroid receptor RNA activator, SRA, and the identification of its biological functions. The key dates are indicated for the discovery
of lncRNA SRA, and characterization of its structure and physiological functions in regulating gene expression, cell differentiation, and development of disease.
contribute in a cooperative way to the overall coactivation.
Consequently, co-transfection of STR1 and STR7 variants with
silent mutations, which impair the SRA secondary structure
without changing the deduced amino acid sequence, almost
totally abolishes SRA coactivation of PR-mediated transcription
(43). Furthermore, a recent study combined chemical probing
(SHAPE, DMS, In-line, or RNase V1) with covariance analysis
across multiple species, which revealed that full-length human
SRA consists of four domains (I–IV) with 25 helices and a
variety of secondary structure elements (45). Importantly, the
secondary structures determined by these chemical probing
studies (45) are consistent with the previously characterized
functional substructure motifs (STRs) (43). For example, RNA
motifs STR1 and STR7 are consistent with the secondary
structural model of helices H2 and H13 (45), respectively. It is
interesting that the previous STR7 region (now H13) is described
as a “hot spot” of protein-RNA interactions and is required to
interact with the SRA-associated proteins SHARP and SLIRP
(47, 48).
SRA1 Gene Evolution
The conservation of the SRA1 gene has been analyzed in terms of
its protein product, SRAP, in all Chordata or certain vertebrates
and species from lower taxa, with the most conserved amino
acids defined as two distinct N- and C-terminal domains (26, 36).
Importantly, by using either ENCODE sequences or Ensemble
data, and comparing the secondary structures of SRA RNA
across vertebrates, it was revealed that evolutionary pressure
preserves the RNA structural core in domains III and IV of SRA,
rather than preserving the structure of SRAP itself (45, 49). This
suggests that the primary functions of SRA1 predominantly relate
to its lncRNA product, rather than those mediated via the SRAP
protein.
SRA Isoforms
Studies in HeLa cells initially identified three isoforms of human
SRA with the same core sequence but different 5′ and 3′ ends
(23). Subsequent work indicated that alternative splicing led to
the generation of coding and various noncoding SRA isoforms
in breast tissues, including the intron-1-containing SRA that
disrupts the SRAP open reading frame (29). A recent study
analyzed the ability of SRA isoforms to modulate activity of the
ETS2 transcription factor, and further validated the existence of
these different isoforms in vivo using 5′ RACE PCR. This revealed
that, in vivo, 35% of SRA transcripts are SRAP-coding while
63% are non-coding isoforms that produce SRA only (33). The
majority of SRA-only lncRNAs consist of differential splicing of
intron 1 (29, 33) or deletion of exon 3 (50), both causing frame
shifts that disrupt the ability to produce SRAP. Exons 4 and 5
were present in more than 99.7% of SRA sequences, whilst exon
2 or intron 1 were present in 86 or 33%, respectively, of total
transcripts (33). The balance between fully spliced and intron-
1-containing SRA RNAs varies among different breast tumors
that have distinct carcinogenic properties. In particular, intron-
1-containing SRA transcripts are enriched in tumors that have
higher progesterone receptor content (51). This suggests possible
links between SRA structure and tumorigenesis. However, before
discussing the pathological implications of SRA, it is worth first
considering its functions in normal physiology and development.
PHYSIOLOGICAL FUNCTION OF SRA
Many recent studies have revealed that SRA has diverse
physiological functions in development and differentiation
(Figure 2A). SRA can exist in both coactivator and corepressor
complexes and has been linked to regulation of NR signaling,
steroidogenesis, mesenchymal fate regulation, and other
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FIGURE 2 | Diverse physiological functions and clinical relevance of SRA and its role in regulating cell cycle and signaling pathways. (A) An array of SRA functions
related to regulation of myocyte and adipocyte differentiation, steroidogenesis and hepatocyte function. SRA transgene (MMTV-SRA) expression in mice led to
aberrant mammary gland development, while SRA gene knockout (SRA−/−) in mice protected them from diet-induced obesity. SRA is also involved in breast and
prostate cancer, cardiomyopathy, and reproductive disorders including polycystic ovary syndrome (PCOS), Normosmic idiopathic hypogonadotroic hypogonadism
(IHH), Endometriosis. Perhaps related to its putative developmental and reproductive health functions, SRA is also expressed in extracellular vesicles (EVs) of human
breastmilk. (B) SRA regulates cell cycle, proliferation and several signaling pathways in cancer cells and adipocytes.
physiological processes. These aspects of SRA biology are
discussed further below.
SRA Regulates NR Signaling
Human SRA was characterized as an RNA coactivator enhancing
transactivation of steroid receptors in an AF-1 domain- and/or
ligand-dependent manner (23, 52, 53). In human cell lines and
Xenopus oocytes, human SRA was shown to form a complex
with p160/SRC-1 proteins, rather than binding directly to steroid
receptors (23); however, recent studies based on filter-binding
assays indicate that, in human cell lines, PR directly binds
to SRA in the absence of hormone (54) and that SRA also
directly interacts with the N-terminal domain (NTD) of ERα and
AR (55). In addition to its interaction with steroid receptors,
we have further shown that human SRA physically binds to
and enhances transcriptional activities of a subset of non-
steroid nuclear hormone receptors, including murine thyroid
hormone receptors (TRs) and steroidogenic factor 1 (SF-1),
and human peroxisome proliferator-activated receptor-gamma
(PPARγ). These interactions are via a unique RNA-binding
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domain present in the hinge regions of TR and SF-1 and in the
N-terminal half of PPARγ (56–59). As we describe further below,
these SRA-NR interactions are relevant to SRA’s regulation of
SF-1-mediated steroidogenesis and PPARγ-mediated adipocyte
differentiation. In addition, mouse or human SRA enhances
retinotic acid receptor (RAR)-mediated transcription (60). Thus,
SRA from mice or humans can coactivate numerous NRs and
regulate their physiological signaling through an NR-SRA axis.
SRA in Steroidogenesis
The NR SF-1 is essential for adrenal development and
steroidogenesis. The atypical orphan NR Dax-1 binds to
and represses SF-1 target genes; however, loss-of-function
mutations of Dax-1 also cause adrenal hypoplasia, suggesting
that Dax-1 may function as an SF-1 coactivator in some
circumstances. Indeed, in Y1 mouse adrenocortical cells we
recently demonstrated that both mouse SF-1 and Dax-1 bind
to human SRA (59). Here, the coactivation of SF-1 by Dax-1 is
abolished by SRA knockdown, leading to reduced downstream
target gene expressions of steroidogenic acute regulator protein
(StAR) and melanocortin 2 receptor (Mc2R) (59). Furthermore,
we have shown that SRA is expressed in mouse embryonic
stem cells (mES) and that Dax-1 augmentation of liver receptor
homolog 1 (LRH-1)-mediated Oct4 activation is dependent upon
SRA expression (61). These findings reveal a crucial function of
SRA in steroidogenesis and adrenal biology.
SRA in Muscle Differentiation
Human SRA is expressed at high levels in skeletal muscle (23),
suggesting possible roles inmuscle development and/or function.
Consistent with this, Caretti and colleagues first indicated that
SRA increases the activity of MyoD, the master regulator
of muscle differentiation, and promotes muscle differentiation
through its associations with the DEAD box-containing and
RNA helicase coregulators, p68 and p72 (62). In addition,
recent studies demonstrated that the role of SRA in promoting
MyoD activity and muscle differentiation is counteracted by the
association of SRAP (33). However, this latter observation was
challenged by a recent study (37), underscoring the need for
additional research to better clarify the specific role of SRA and
SRAP in muscle cell differentiation.
SRA in Adipogenesis
SRA expression is two-fold higher in mouse adipocytes than in
preadipocytes (56), based on which we investigated if, as for
muscle differentiation, SRA might also modulate adipogenesis.
We discovered a novel function of SRA as a stimulator of mouse
adipocyte differentiation via directly binding to and promoting
the transcriptional activity of PPARγ (56), the master regulator
of adipogenesis. Notably, this is the first example of lncRNA
function in adipogenesis. Microarray analysis reveals hundreds
of SRA-responsive genes in mouse adipocytes themselves, which
suggests further functions of SRA in these fully differentiated
cells. We further revealed that SRA promotes adipogenesis
and regulates insulin sensitivity in mouse adipocytes not only
by acting as coactivator for PPARγ, but also via multiple
additional mechanisms. These include promoting S-phase entry
during the mitotic clonal expansion phase of adipogenesis;
controlling cell cycle gene expression; inhibiting the expression
of adipocyte-related inflammatory genes; and suppressing TNFα-
induced phosphorylation of c-Jun NH2-termianl kinase, which
is implicated in the development of insulin resistance in mouse
adipose tissue (56). In addition, in the mouse bipotential ST2
mesenchymal cell line, SRA can also regulate adipogenesis by
inhibiting phosphorylation of p38/JNK during the early stages
of adipogenesis, as well as stimulating insulin receptor gene
expression and downstream signaling (44).
SRA Expression in Human Breastmilk
The above observations underscore the function of SRA in
regulation of cell fate. Development is regulated not only at
this cell-fate level, but also through developmental programming
that occurs in utero and perinatally. The latter is strongly
influenced by adequate nutrition, which, in mammals, is related
to breastmilk availability. Indeed, breastmilk contains nutrients,
milk fat globules, hormones, growth factors, immune component
cells, antibodies, cytokines, and extracellular vesicles (EVs),
and plays an important role in infant development (63, 64).
Recent studies suggest an unexpected role of SRA and other
lncRNAs in these aspects of development. EVs are small double-
lipid membrane vesicles found in a number of body fluids
including breastmilk, and regulate cell-cell communications
through specific interaction with target recipient cells (65, 66).
A recent study has revealed that a subset of lncRNAs, including
SRA1, GAS5, and CRNED, are expressed in EVs of human
breastmilk (67). The implications of this remain unknown, and
therefore future studies will be crucial to reveal the functional
role of SRA in breastmilk; however, this observation suggests that
the ability of SRA to impact development may extend beyond
regulation of cell fate, including possible influences on mother-
to-child signaling.
In vivo Functions of SRA
Lanz and colleagues generated MMTV-SRA transgenic mice,
which overexpress a 1.3 kb human SRA under the control of the
mouse mammary tumor virus (MMTV) promoter (68). These
MMTV-SRA transgenic mice have abnormal mammary gland
development characterized by ductal ectasia, acinar hyperplasia,
and intraductal proliferation of luminal epithelial cells, but
accompanied by increased apoptosis in the stratified epithelia.
ER is the major proliferative driver in breast cancer, and SRA-
mediated coactivation of the ER contributes to the increased
luminal cell mitosis during mammary gland development of
these transgenicmice. In addition, bothmale and femaleMMTV-
SRA transgenic mice have reduced fertility, probably due to the
impact of SRA on activity of sex steroid receptors.
We have recently revealed that, inmice, SRA is expressedmost
highly in white and brown adipose tissues compared to other
tissues (42). This underscores SRA’s potential function in adipose
tissue formation. To further elucidate SRA function in vivo, the
first mouse model of global SRA gene knockout (SRA−/−) was
generated (42). Consistent with the pro-adipogenic function of
SRA in vitro, these SRA−/− mice have phenotypes of resistance
to high-fat diet-induced obesity, with decreased fat mass and
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increased lean mass; decreased adipocyte gene expression;
reduced fatty liver; and improved glucose tolerance. These data
are the first in the field to indicate a functional role of lncRNA
in adipose tissue biology and glucose homeostasis in vivo. This
putative role of SRA in metabolic health is discussed further
below (see section SRA, Obesity, and Fatty Liver).
MOLECULAR MECHANISMS OF SRA
ACTION
We have described that SRA has diverse physiological functions
in regulation of NR signaling, myocyte, and adipocyte
differentiation. SRA is also implicated in the pathogenesis
of breast and prostate cancers, as we discuss later in this review.
Given these diverse functions, it is perhaps not surprising that
SRA exerts these effects via various mechanisms and signaling
pathways (Figures 2, 3).
SRA Functions as a Scaffold
As described above, SRA regulates NR transcriptional activities
through directly or indirectly interacting with NRs (Table 1 and
Figure 3). SRA also interacts with other TFs, such as MyoD (62),
Oct4 (61), Nanog (73), and FOXO1 (74); and forms a complex
with coregulators of NRs and TFs, such as SRC-1 (23), P68
(62, 69), PUS1/3 (71, 75), components of RISC complex proteins
(PACT, TRBP, Dicer, and Argonaut2) (72), and repressive
coregulatory proteins SHARP (48) and SLIRP (47). This suggests
that SRA works in concert with these interacting partners
to regulate target gene expression. We describe below how
SRA also binds to the components of chromatin modification
complexes to regulate gene expression (Table 1 and Figure 3).
Thus, SRA functions as an RNA scaffold to regulate transcription
by recruitment of various regulatory molecules to transcriptional
coactivator or corepressor complexes. In addition, STR7, one
of the functional stem-loop substructures of SRA, is important
for SRA’s ability to recruit its interacting protein partners SLIRP
and SHARP to DNA promoter sites (47). In contrast, the STR1
substructure mediates SRA binding to PACT, TRBP, and PKR,
thereby regulating their recruitment to target promoters (72).
SRA Post-transcriptional Modifications
Zhao and colleagues demonstrated that a pseudouridine synthase
(PUS), mPus1p, can function as a coactivator for mouse retinoic
acid receptor gamma (mRARγ) and other nuclear receptors (60).
They further revealed that mPus1p pseudouridylates SRA, and
that co-transfection of mPus1p and SRA cooperatively enhances
mRARγ-mediated transcription. mPus3p also pseudouridylates
SRA, although it may target different positions of SRA than
those targeted by mPus1p (71). An additional study found that
uridine at 206 of SRA (U206) is the common target position
for both mPus3p and mPus1p, whose specificity may depend
on specific cellular contexts and which may influence whether
SRA functions as coactivator or corepressor (71). U206 is located
within the stem-loop substructure STR5 of the core conserved
SRA [also defined as helix 7 within the newly characterized SRA
full secondary structure (45)]. STR5 has been shown, at least in
part, to contribute to the full activity of SRA (43). Interestingly,
synthetic STR5 can inhibit Pus1p-mediated pseudouridylation
of SRA, and has higher efficiency than mutant SRA-U206A
to inhibit transactivation of ERα and AR. This suggests that
STR5 could be a novel therapeutic target in control of NR
transcriptional activity (55).
SRA Regulates the Cell Cycle
Lanz et al. first recognized the role of SRA in regulating
cell proliferation via studies of mammary epithelial cells (68).
We recently further revealed that SRA also promotes S-phase
entry during mitotic clonal expansion of preadipocytes, which
occurs shortly after the induction of adipogenesis. Here, SRA
decreases expression of the cyclin-dependent kinase inhibitors
p21Cip1 and p27kip1 and increases the phosphorylation of Cdk1
and Cdc2, suggesting that the ability of SRA to regulate the
cell cycle may be independent of its coactivation of PPARγ
(56). In addition, SRA knockdown reduces ligand-induced cell
proliferation of T47D cells, andmicroarray analysis revealed that,
among SRA-affected genes, there is enrichment for gene ontology
(GO) terms related to apoptosis and cell proliferation (54)
(Figure 2B). Thus, these observations demonstrate the ability of
SRA to regulate the cell cycle across diverse cell types.
Genome-Wide SRA-Responsive Genes
Recently, three groups have reported the identification of
genome-wide SRA-responsive genes in breast cancer cells or
adipocytes. Foulds and colleagues used siRNAs to deplete SRA
in HeLa cells and MCF-7 human breast cancer cells, followed
by microarray analysis of the transcriptional consequences (76).
They found that the majority of significantly changed genes
are downregulated by SRA knockdown, consistent with SRA
functioning as a coactivator. In HeLa cells, 4030 probe sets
are differentially regulated following SRA knockdown. In MCF-
7 cells, 780 transcripts are differentially regulated by SRA
knockdown and E2 induction, although only a small subset of
these genes are direct targets of ERα. This suggests that SRA is
not impacting gene expression via modulation of ERα activity.
Instead, GO analysis reveals that in HeLa cells SRA may play
roles in protein targeting to membranes, transporting metal ions
and lipids/cholesterol, as well as affecting fatty acid biosynthesis;
while in E2-treated MCF-7 cells, GO data suggests possible
SRA functions related to thyroid metabolism, such as reduced
expression of DIO2.
Another study investigated the transcriptional consequences
of SRA knockdown in the T47D breast cancer cell line, in
comparison to PR target genes. Here, 2,343 transcripts were
found to be regulated by treatment with R5020, a PR agonist,
among which 466 transcripts (20%) were also affected by SRA
knockdown (54). Interestingly, among these 466 SRA-responsive
genes, 60% were up-regulated and 40% were down-regulated
by SRA knockdown and R5020 treatment. GO analysis further
indicated that SRA-responsive genes are involved in regulation of
transcription and phosphorylation, cell proliferation, apoptosis,
DNA binding, intracellular signaling cascades, and signal
transduction. Thus, these roles may differ to those observed
above for SRA-responsive genes in HeLa and MCF-7 cells.
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interacting with protein partners in both activating and repressive complexes. SRA also regulates the activity of transcription factors including nuclear receptors (NRs),
MyoD, Oct4, and FOXO1; coregulators; and components of chromatin modification factors. PUS, pseudouridine synthase; RISC, RNA-induced silencing complex;
Trxn, trithorax complex; SHARP, the SMRT/HDAC1 associated repressor protein; SLIRP, SRA stem-loop interacting RNA binding protein; CTCF, CCCTC-binding
factor; HP1γ, heterochromatin protein 1γ; and LSD1, lysine-specific demethylase 1; PRC2, polycomb repressive complex 2.
The above transcriptomic analyses illustrate the diverse
mechanisms through which SRA’s transcriptional regulatory
actions might impact cell biology. To further address this,
we have recently identified SRA-responsive genes in SRA-
overexpressing ST2 adipocytes and SRA knockdown 3T3-L1
adipocytes (56). In SRA-overexpressing ST2 adipocytes, 1687
genes/expressed-sequence tags (EST) are significantly changed.
Among these, 421 (25%) were up-regulated and 1,266 (75%)
were down-regulated by SRA overexpression. For 3T3-L1
adipocytes, the expression of 340 genes/ESTs was differentially
regulated (145 up, 195 down) by SRA knockdown. In the ST2
adipocytes, GO analysis revealed that SRA overexpression is
associated with enrichment of genes related to calcium ion
binding, receptor activity, actin binding, molecular transducer
activity, extracellular matrix structural constituents conferring
tensile strength, and GTPase action. In 3T3-L1 adipocytes, SRA
knockdown is associated with enrichment for genes involved in
cell adhesion, phosphate transport, collagen fibril organization,
transmembrane receptor protein tyrosine kinase signaling,
axon extension, and multicellular organismal development.
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TABLE 1 | Protein partners of lncRNA SRA.
Proteins Direct interaction Complex formation Functions References
PR x Enhances PR transactivation (23, 54)
AR x Enhances AR transactivation (23, 55)
GR x Enhances GR transactivation (23)
ER x Enhances ER transactivation (23, 55)
TR x Enhances TR transactivation (57, 58)
RAR x Enhances RAR transactivation (60)
MyoD x Enhances MyoD transactivation (62)
SF-1 x Enhances SF-1 transactivation (59)
Dax-1 x SRA/Dax-1 play in concert for SF-1 transactivation (59)
PPARγ x Coactivator of PPARγ (56)
SRC-1 x Forms a ribonucleoprotein for coactivation (23)
P68 x Forms complexes with MyoD & component of chromatin (62, 69, 70)
P72 x Forms complexes with MyoD (62)
Pus1p x Plays in concert for NR coactivation (60, 71)
Pus3p x Plays in concert for NR coactivation (71)
CTCF x Increases CTCF insulator activity (69)
SHARP x SHARP represses SRA’s coactivation to NR (48)
SLIRP x Recruits SLIRP to binding sites (47)
HP1γ x Forms a complex with PR-HP1γ-LSD1 for repression (54)
LSD1 x Forms a complex with PR-HP1γ-LSD1 for repression (54)
PACT x Forms a complex to promote NR activity (72)
TRBP x Forms a complex to promote NR activity (72)
Dicer x Forms a complex to promote NR activity (72)
Argonaute2 x Forms a complex to promote NR activity (72)
NANOG x Enhance NANOG transcriptional activity (73)
WDR5 x Forms TrxG complex for activation (73)
MLL1 x Forms TrxG complex for activation (73)
MLL2 x Forms TrxG complex for activation (73)
EZH2 x Forms PRC2 complex for repression (70, 73)
RBBP5 x Forms TrxG complex for activation (73)
ASH2L x Forms TrxG complex for activation (73)
EED x Forms PRC2 complex for repression (73)
SUZ12 x Forms PRC2 complex for repression (73)
OCT4 x Enhances OCT4 transcriptional activity (61)
FOXO1 x Represses FOXO1 transcriptional activity (74)
The mechanisms and functional implications of these diverse
transcriptional effects remain to be fully elucidated. However,
these observations highlight the diverse pathways through which
SRA might impact physiology and disease. These pathways are
further discussed below.
SRA Regulates Multiple Signaling
Pathways
As described above, in both cancer cells and adipocytes, SRA-
responsive genes include those involved in transmembrane
receptor-mediated signal transduction, suggesting that SRA
may regulate pathways responsive to extracellular effectors
(Figure 2B). Indeed, we found that SRA overexpression inhibits
the expression of a subset of negative regulators of insulin
sensitivity, such as SOCS-1/-3, Pkca, and Foxc2 (56). This
is in agreement with the finding that SRA increases insulin-
stimulated glucose uptake and phosphorylation of Akt and
FOXO1 in mature adipocytes. In addition, gene set enrichment
analysis (GSEA) identifies SRA-responsive and functionally
related gene sets enriched in TNFα signaling. This finding
was further confirmed by experiments showing that SRA
inhibits TNFα-induced JNK phosphorylation. To assess the
mechanism, our recent study further demonstrated that SRA
overexpression inhibits the phosphorylation of p38 MAPK and
JNK, while SRA knockdown increases JNK phosphorylation (44).
Furthermore, knockdown of SRA in 3T3-L1 mature adipocytes
led to decreased insulin receptor (IR) mRNA and protein
levels, thereby leading to decreased autophosphorylation of
IRβ and decreased phosphorylation of IR substrate-1 (IRS-
1) and Akt. This effect likely reflects a stimulatory role
of SRA on IR transcription (44). Recently, we have also
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shown that SRA enhances insulin signaling in hepatocytes
(74). Taken together, these data suggest that SRA promotes
adipocyte differentiation and insulin sensitivity through up-
regulating insulin signaling and simultaneously inhibiting
signaling downstream of TNFα, which otherwise would promote
insulin resistance.
Interestingly, a recent study revealed that SRA associates with
the RNA helicase Ddx5/p68 in murine Beko pre-T cells, and acts
as a coactivator in the Notch signaling pathway (77) (Figure 2B).
It remains possible that SRA might also modulate insulin, TNFα
and/or Notch signaling pathways in cancer cells and other cell
types, thereby regulating cell proliferation and differentiation;
however, this possibility remains to be addressed.
SRA in Activating and Repressive
Complexes
Most early studies, based on reporter gene assays, revealed that
SRA functions as a scaffold to coactivate multiple transcriptional
activities of NRs. The molecular mechanisms underlying this
coactivator function have begun to be elucidated (Figure 3).
Thus, SRA has been shown to form a complex with the p160
coactivator SRC-1, indicating that SRAmaymodulate the activity
of NRs by forming a distinct activating complex (23, 78).
Subsequent studies have revealed that SRA also can form a
complex with the p68/p72 RNA helicases to coactivate MyoD
transcription and stimulate expression of downstream target
genes (62). In addition, we have shown that SRA binds to Dax-
1 to coactivate transcriptional activity of SF-1 in steroidogenesis,
and to augment liver receptor homolog 1 (LRH-1)-mediated
Oct4 activation (59, 61). A recent study further demonstrated
that SRA functions as a scaffold binding to the RNA-induced
silencing complex (RISC) proteins PACT, TRBP, and Dicer to
activate a subset of NRs, including ER, GR, and AR (72).
However, SRA can also suppress NR transactivation by binding to
nuclear repressors such as SHARP (the SMRT/HDAC1 associated
repressor protein) (48) and SLIRP (SRA stem-loop interacting
RNA binding protein) (47). These observations suggest that SRA
also plays a repressive role for gene expression in some cellular
contexts. Indeed, a recent study further revealed that SRA binds
to PR, HP1γ (heterochromatin protein 1γ), and LSD1 (lysine-
specific demethylase 1), and its depletion compromises the
loading of the repressive complex to target chromatin-promoting
aberrant gene de-repression. These data indicate that SRA exists
in a repressive complex containing HP1γ, LSD1, HDAC1/2,
CoREST (corepressor for REST [RE1-neuronal repressor element
1] silencing transcription factor), and demethylase KDM5B (54).
In addition, unliganded PR binds genomic sites and targets
this SRA-containing repressive complex to 20% of hormone-
inducible genes, maintaining these genes in a silenced state
prior to hormone treatment. Thus, in this class of target genes,
SRA may play a repressive role (54) (Figure 3). As discussed
below, we also recently showed that SRA inhibits forkhead box
protein O1 (Foxo1) transcriptional activity in hepatocytes (74).
Therefore, our current model suggests that SRA can exist in
both coactivator and repressor complexes to either promote or
inhibit transcriptional activity of NRs or other TFs. The switch
to determine if SRA activates or inhibits gene expression may
depend on the cellular context, for example in response to
hormones or other specific physiological stimuli (Figure 3).
SRA in Chromatin Modification and
Epigenetic Regulation
Chromatin insulators are DNA elements that can protect a gene
from outside influence, leading to either inappropriate activation
or silencing of the gene (79, 80). CTCF is a DNA-binding protein
that can control higher-order chromosomal looping and insulate
specific genes from the effects of long-range enhancers and
regulatory elements (81). Yao and colleagues recently revealed
that SRA/p68 form a complex with CTCF that is essential for
insulator function in HeLa cells (69). Knockdown of SRA or p68
reduced the CTCF-mediated insulator activity at IGF2/H19 ICR,
increased the expression of IGF2 and increased the interaction
between the endodermal enhancer and the IGF2 promoter. SRA
also interacts with members of the cohesin-binding complex, and
knockdown of SRA reduces cohesin binding although this does
not affect CTCF genomic-binding sites.
Increasing evidences demonstrate that lncRNAs can
target diverse chromatin regulators and several chromatin
modifications (10, 16). Modification of histone 3 by lysine
4 trimethylation (H3K4me3) and lysine 27 trimethylation
(H3K27me3) represent activating and repressive histone marks,
respectively. When they present together as bivalent chromatin
domains, they control the precise gene expression programs
during pluripotency and differentiation that are poised for
induction (82). There are two distinct histone modification
machineries including complexes of the trithorax (TrxG) and
polycomb repressive complex 2 (PRC2), which are responsible
for methylation of H3K4 and H3K27, respectively. As shown in
Figure 3, SRA binds to a subset of proteins belonging to both
TRxG and PRC2, thereby regulating the formation of these
complexes. One recent study indicated that, in mouse embryonic
stem cells, SRA can interact with EZH2, a component of PRC2
(70). Similarly, in human pluripotent NTERA2 stem cells, SRA
associates with TRxG components via specific interactions with
WDR5, while in the PRC2 complex SRA directly binds to SUZ12
and EED (73). This study further revealed that SRA-associated
p68 stabilizes SRA’s interaction with TrxG, but not PRC2
(73). By using the technique of chromatin isolation by RNA
purification (ChIRP) (83), 7,899 SRA genome-wide binding sites
were identified to colocalize with bivalent domains for both
H3K4me3 and H3K27me3 in NTERA2 stem cells (73). The same
report also indicated that, in these stem cells, the transcription
factor NANOG directly interacts and co-localizes with SRA on
a genome-wide level, with this interaction being important for
maintaining the stem cell pluripotent state. Although RNA-seq
analysis for gene expression has not been reported in this study,
these SRA-binding sites are likely the direct genome-wide targets
that SRA regulates. These data suggest that, at least in stem
cells, SRA likely regulates gene expression and cellular function
by forming complexes with TrxG and PRC2 proteins, thereby
establishing bivalent H3 methylation domains. This epigenetic
mechanism may also recruit diverse DNA-binding factors that
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are able to activate or repress transcription in response to various
cellular signaling pathways (Figure 3). However, it remains
unknown if these epigenetic functions of SRA extend beyond
stem cells. Thus, it will be crucial to investigate if SRA applies
similar mechanisms to regulate the function of cancer cells and
other cell types.
SRA AND HUMAN DISEASE
The need to understand these mechanisms in the context of
cancer is particularly important, because there are increasing
evidences showing that SRA plays an important role in the
development of breast and prostate cancers. However, SRA
has also been implicated in the pathogenesis of other diseases
(Figure 2A). Consequently, there could be great therapeutic
benefit to better understanding the mechanisms through which
SRA impacts cancer and other disease states.
SRA and Breast Cancer
SRA expression is significantly up-regulated in human tumors
of steroid-responsive tissues including the breast, uterus and
ovary (50, 68). One study revealed that breast cancer cells
generate both SRAP-coding and non-coding SRA isoforms by
alternative splicing (29). Furthermore, in T5 breast cancer cells,
increases in the ratio of non-coding SRA (intron-1-contiaing)
to SRAP-coding transcripts resulted in elevated expression of
genes associated with cancer cell invasion and tumor progression
(51). In contrast, SRAP levels were significantly higher in ERα-
positive and PR-positive breast cancer biopsies, identifying SRAP
as a potential new prognostic marker for breast cancer patients
(84). A recent study further indicated that overexpressing SRAP
increases breast cancer cell motility (85).
Other data support a direct role for SRA that may be
independent of ERα action. For example, depletion of SRA in two
human breast cancer cell lines significantly reduced expression of
the majority of SRA-responsive genes, suggesting a coactivating
role of SRA (76). However, this study indicated that only a small
subset of direct ERα-target genes was affected in estradiol-treated
MCF-7 cells, in which SRA depletion led to decreased expression
of some genes (such as THBS1, CAV1, TMPRSS2, and TMPRSS3)
tightly associated with invasion/metastasis. Furthermore, SRA
depletion in ERα-negative MDA-MB-231 cells decreased the
expression of some genes important for invasiveness (such as
CAV1, TMPRSS2, and 12 MMPs), and this was reflected in
decreased invasive behavior of the SRA-depleted cells (76). In
general, these experiments suggest that the effect of SRA on
breast cancer may be less ER dependent than initially expected.
In contrast, a recent case study evaluated the association between
breast cancer risk and two haplotype tagging SNPs (htSNPs)
(rs10463297, rs801460) within the SRA1 locus (86). This case
study indicated that these SRA htSNPs are significantly associated
with ER positivity status and this may contribute to breast cancer
risk and progression.
SRA and Prostate Cancer
Recent studies indicate that SRA and other lncRNAs, such as
PCA3, PCAT-1, and SCHLAP1, are involved in the progression
of prostate cancer (87–91). For SRA this relationship may relate
to effects of both the lncRNA and SRAP. For example, three SRAP
isoforms are expressed in human prostate cell lines (34), and
transfection of SRAP-coding SRAs promotes AR transcriptional
activity in several prostate cancer cells (such as PC-3, DU-
145, and LNCaP cells) (92). Conversely, knockdown of SRA
inhibits AR activity in LNCaP and PC-3 cells (92). These data
support the conclusion that SRA and SRAP influence prostate
cancer by coactivating the AR. Consistent with this, in AR-
positive LNCaP cells, knockdown of SRA results in reduced
proliferation and decreased expression of TMPRSS2, but not PSA
and PMEPA1 (93). However, SRA knockdown also exerts these
effects in DU145 cells, which are AR-negative (93), suggesting
that SRA also exerts AR-independent effects to modulate prostate
cancer progression. Whether these AR-independent effects are
mediated via SRA or SRAP remains to be determined. Indeed,
since the knockdown of the SRA1 gene depletes both SRA
and SRAP, future experiments are required to distinguish the
functions of SRA and SRAP in the pathogenesis of prostate
cancer.
SRA, Obesity, and Fatty Liver
Lanz and colleagues have shown that SRA expression is enriched
in human liver and muscle tissues (23), key organs in the
regulation of metabolic homeostasis. Interestingly, the previously
described MMTV-SRA transgenic mice not only display a
phenotype of increased cellular proliferation, differentiation, and
ductal-epithelial hyperplasia; they also present with pronounced
multilocular fat, including an increased density of fat droplets
in mammary glands of adolescent MMTV-SRA mice (68).
Consistent with this putative role of SRA in regulating adipose
development in vivo, we recently revealed that, in wild-type
mice, SRA is expressed most highly in adipose tissues (42). To
directly assess the role of SRA in adipose tissue development, we
generated the first mouse model with a whole-body knockout
of SRA (SRA−/−). We have found that SRA−/− mice are
resistant to high-fat diet (HFD)-induced obesity, with decreased
fat mass and increased lean mass (42). This lean phenotype
of SRA−/− mice is associated with decreased expression of a
subset of adipocyte marker genes in adipose tissues, as well as
reduced plasma TNFα levels. The latter is notable given that
obesity is associated with increased production of TNFa within
adipose tissue, which may contribute to metabolic dysregulation.
Indeed, the SRA−/− mice are more insulin sensitive than their
wild-type counterparts; have reduced fatty liver after HFD
feeding; and have decreased expression of hepatic lipogenesis-
associated genes. Adipose triglyceride lipase (ATGL) is a major
triacylglycerol (TAG) hydrolase that acts as a key regulator
of hepatic lipid metabolism. Our recent study demonstrated
that loss of SRA in hepatocytes upregulates ATGL expression
and the β-oxidation of free fatty acids (FFA), whereas forced
expression of SRA inhibits these outcomes (74). Furthermore,
SRA represses ATGL expression primarily by inhibiting the
inductive effects of Foxo1. Along with the previously discussed
effects of SRA on adipogenesis and adipocytes in vitro, these
data suggest that SRA may be a potential target to control
HFD-induced obesity, fatty liver and glucose homeostasis in
Frontiers in Medicine | www.frontiersin.org 10 September 2018 | Volume 5 | Article 244
Sheng et al. New Insight of lncRNA SRA Function
vivo. One key remaining question is whether SRA also impacts
metabolic health in humans. For example, are SNPs in SRA1
associated with altered adiposity, hepatic lipid content and/or
other metabolic outcomes? Such genome-wide human studies
will be important to pursue if we are to better understand
the interplay between SRA and metabolic homeostasis in
humans.
SRA and Cardiovascular Disease
In a recent genetic study to identify genes responsible for
the pathogenesis of human dilated cardiomyopathy, SRA
emerged as one of the key candidate genes (94). To functionally
address this possibility, the authors treated fertilized zebrafish
eggs with antisense morpholinos against SRA, thereby
decreasing SRA expression. This resulted in a phenotype of
myocardial contractile dysfunction with impaired contractility,
predominantly in ventricular heart chambers at the early stage
of heart development (94). Previous studies have established
roles for the thyroid hormone and glucocorticoid receptors
in cardiac function (95, 96); hence, given the ability of SRA
to impact NR action, one possibility is that depletion of
SRA leads to defective heart development as a result of
decreased activity of these NRs. However, this possibility
remains speculative, and the mechanisms linking SRA to
cardiovascular function in zebrafish remain to be elucidated.
More importantly, future studies must address if SRA also
impacts cardiovascular health in higher organisms, including
functional studies in mammalian systems and genetic studies in
human populations.
SRA and Diseases of Reproductive Health
Polycystic ovary syndrome (PCOS) is one of the most
common heterogeneous endocrine and metabolic disorders.
PCOS accounts for 75% of anovulatory infertility and is highly
associated with obesity, insulin resistance, dyslipidemia and
increased risk of diabetes and cardiovascular events (97). A recent
case study revealed that SRA expression in peripheral blood
leukocytes was significantly higher in women with PCOS than
in healthy control individuals (28). However, at this stage it
remains unknown if altered SRA expression contributes to the
pathogenesis of PCOS, highlighting this topic as another area for
future investigation.
Other recent case studies have identified three independent
families with inactivating SRA1 mutant variants (missense
mutations including P20L, Q32E, Y35N, or I179T) that
are associated with delayed puberty/normosmic idiopathic
hypogonadotroic hypogonadism (IHH) (25). This disease is
characterized by an inability to develop secondary sexual
characteristics and a mature reproductive system, owing to
defects in the central part of the hypothalamic-pituitary-
gonadal axis (98). These case studies suggest that SRA1 gene
function may be required for the initiation of puberty in
humans.
In addition to PCOS and IHH, two final studies implicate SRA
in the pathogenesis of endometriosis, an estrogen-dependent
disease that affects about 10% of reproductive-aged women.
Interestingly, Lin and colleagues reported that SRA RNA
and ERα protein expression are higher in endometrial tissue
compared to ovarian tissue surrounding mature teratoma
and ovarian endometrioma (27). In contrast, higher protein
expression of SRAP and ERβ were shown in surrounding
ovarian tissue than in ovarian endometrioma and ovarian
tissue surrounding mature teratoma. In human primary
endometriotic stromal cells, knockdown of the SRA gene
increases ERα but decreases ERβ expression, as well as
attenuates cell proliferation and promotes early apoptosis
when cells are treated with E2 (99). These observations
suggest that SRA/SRAP may act in concert to regulate the
function of ERα and ERβ in the pathogenesis of ovarian
endometrioma.
In summary, studies relating to the pathogenic roles of SRA
have focused largely on breast and prostate cancers, as well
as metabolic diseases such as obesity-related insulin resistance
and hepatic steatosis. Other studies are beginning to highlight
potential roles of SRA in other diseases, including cardiovascular
disease and reproductive disorders such as PCOS, IHH, and
endometriosis. Future studiesmust now build on these promising
findings, in particular through human analyses, so that we can
better understand the pathogenic roles of SRA.
FUTURE QUESTIONS AND THERAPEUTIC
IMPLICATIONS
It has been almost two decades since the discovery of the
lncRNA SRA. However, many aspects of SRA biology remain
to be elucidated. For example, what is its exact physiological
function? Through what molecular mechanisms does SRA
regulate gene expression, development, and cell differentiation?
Finally, how does SRA impact the pathogenesis of cancers and
other diseases?
In terms of molecular mechanisms, we now know that
SRA exists in the ribonucleoprotein complex that includes
SRC-1 and binds to components of proteins belonging
to both the TrxG and PRC2 complexes, which regulate
chromatin’s epigenetic state. SRA also binds to numerous
protein partners including NRs and other transcription factors
and coregulators. Thus, it is crucial to further identify
the dynamic SRA-binding proteins or RNAs in living cells,
including how these interactions are influenced by hormones
or other physiological conditions. ChIRP is one approach
that has much promise in revealing this new knowledge. In
addition, how SRA-binding sites are regulated by different
extracellular signals, in a cell-context dependent manner,
is largely unknown. Therefore, it is necessary to identify
SRA genome-wide binding sites and analyze their association
with gene expression under specific differential conditions,
developmental stages and in different cell types, such as during
adipogenesis or breast cancer cell oncogenesis. This knowledge
would improve our understanding of SRA’s transcriptional
targets and how these impact physiological and pathological
processes.
A related question is, how is SRA recruited to chromatin?
Clearly, this recruitment may be via known SRA-interacting
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partners, including NRs, other transcription factors (such as
MyoD), coregualators (p68), and components of chromatin
regulatory complexes (LSD1, TrxG, and PRC). However,
other lncRNAs employ more diverse mechanisms, including
the formation of RNA:DNA:DNA triplexes; generation of
RNA:DNA hybrids that displace a single strand of DNA; or
creation of an RNA:RNA hybrid between a lncRNA and a
nascent transcript (10, 16). Does SRA also utilize any of
these mechanisms to modulate gene expression? The ability
of lncRNAs to bind to protein partners embues them with
diverse regulatory properties. For example, it is possible that
SRA plays a role through “decoys” that preclude the access
of regulatory proteins to DNA, and/or through “guides” that
facilitate correct localization of specific protein complexes
(16). Clearly, these possibilities must be investigated in future
studies.
Increasing evidences indicate that SRA can both activate
and repress gene expression (Figure 3). Although recent studies
indicate that SRA binds to components of both activating
(TrxG) and repressive (LSD1 and PRC2) complexes, the precise
mechanism involved is yet to be determined. Thus, it remains
unclear if these interactions are further regulated, for example
in response to stimuli related to different temporal and spatial
aspects of development and cell differentiation. In addition, SRA
also exists in other activating complexes (SRC1, p68, TIF2/Dax-
1) and repressing complexes (SHARP and SLIRP/HDAC);
how SRA works in concert with all these transcriptional
coregulators and components of chromatin regulatory complexes
(TrxG, LSD1, and PRC2) must be a focus of future research
(Figure 3).
We and others have shown that SRA regulates insulin, TNFα
and Notch signaling pathways, but many questions remain.
For example, what is the molecular mechanism underlying this
regulation? What are the upstream direct targets (transcription
factors or signaling proteins) that regulate SRA function in
response to these signaling pathways?
To determine the precise physiological function of SRA,
it is crucial to establish the phenotypes of animal models
of SRA gain- and loss-of-function, as well as the underlying
mechanisms. Currently, neither transgenic MMTV-SRA mice
(68) nor our SRA-/- mouse model can fully address this issue,
because MMTV-SRA is expressed only in steroidal tissues and
SRA−/− mice lose both SRA and SRAP in all tissues (42). Future
combined approaches could use CRISPR-Cas9 (100) to restore
SRA or SRAP in ectopic sites (101, 102) under the SRA−/−
genetic background, or to delete endogenous SRA or SRAP on
a tissue-by-tissue basis. Such highly specific approaches could
more robustly address the physiological functions of SRA and
SRAP in a tissue-specific manner.
Differential splicing of SRA must also be more closely
investigated. As discussed above, some breast cancer tumor cells
have high expression of intron-1-containg SRA, relative to the
SRAP-encoding variants. Future studies must further address
whether this pattern of elevated intron-1-containg SRA (relative
to fully spliced SRA or other non-SRAP-coding SRA isoforms)
occurs in other developmental or pathological contexts. For
example, is the intron-1-containing SRA also enriched in
the adipose tissue or liver of obese individuals, compared
to healthy non-obese controls? These splicing processes are
regulated by trans-acting proteins (repressors or activators) and
corresponding cis-acting sites in the DNA promoter sequence of
the SRA1 gene. How these elements form a “splicing code” to
regulate splicing under different physiological conditions (103,
104) is yet another subject for future study. Furthermore, what
upstream regulatory mechanisms underlie the increased SRA
expression in breast cancer cells, during adipocyte differentiation,
and in fatty liver? Similarly, how is SRA expression regulated in
response to the external stimuli and specific signaling pathways?
These questions remain to be answered.
LncRNAs have been emerging as factors that provide a new
layer for regulation of gene expression in numerous biological
contexts, including cell differentiation, development, physiology,
and disease. In addition to being a potential biomarker for
breast cancer, the differential expression of SRA and genetic
mutations have been connected to other diseases such as
POCS, IHH, endometriosis, and cardiovascular dysregulation.
However, only a handful of studies have reported a role for
SRA in these contexts, underscoring the need for additional
research.
SRA as a Novel Therapeutic Target
Experimental therapeutic agents targeting lncRNAs are only
in their infancy. The characterization of the precise secondary
structures of SRA promises to open new strategies. For
example, it might be possible to target specific stem loop
structures of SRA to more precisely modulate activities of
nuclear receptors (55) and other transcription factors, and/or
to impact epigenetic effects in the pathogenesis of SRA-
related diseases. This improved understanding of SRA structure
may also facilitate rational design of more precise SRA
antisense oligonucleotides and/or other forms of knockdown
methods that will allow finer modulation of SRA function. The
aforementioned trans-acting proteins and corresponding cis-
acting sites that are involved in regulating SRA splicing are
also potential targets for controlling the production of disease-
causing isoforms of SRA, such as the non-SRAP-coding intron-
1-containing variant. This is exemplified by studies targeting
regulatory elements in the H19 gene as an approach for
pancreatic cancer therapy (105). Furthermore, more recent
studies using engineered CRISPR-interference (CRISPRi) or
CRISPR-activation (CRISPRa) can control gene expression at
target promoters (106, 107). For example, two recent studies
successfully proved that the promoter sequence of lncRNAs
can be used as a target to regulate the gene expression
and splicing of themselves and their neighboring genes (108,
109). Therefore, gene editing via CRISPR-Cas9 might allow
tissue-specific manipulation of SRA expression as an improved
precision-medicine approach.
CONCLUDING REMARKS
Much progress has beenmade in understanding the physiological
and pathological functions of SRA, and some light has been
shed on the underlying molecular mechanisms. However, from
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this review it is clear that many, many questions remain to be
answered. Nevertheless, SRA and other lncRNAs display promise
as biomarkers and therapeutic targets that might allow new
strategies for improved clinical outcomes. To realize this promise,
it is essential that future research yields further insights into
the physiological and pathological roles of SRA, as well as the
molecular mechanisms of its action.
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